Growing Research Collaborations NCCS actively partners with leading biopharmaceutical companies and genomics firms such as Elpis Biopharmaceuticals, Illumina, PacBio, and Agilent Technologies, indicating a strong potential for providing advanced research tools, sequencing solutions, and molecular profiling technologies.

Expanding Capacity and Facilities The inauguration of the new NCCS building in 2023 with expanded infrastructure for research and treatment presents opportunities to introduce innovative medical devices, advanced equipment, and digital health solutions to support enhanced cancer care and research activities.

Focus on Precision Oncology Collaborations on cancer genomics and molecular profiling highlight NCCS’s emphasis on precision medicine, opening avenues for selling genomic testing platforms, biomarker analysis tools, and AI-driven data analytics for personalized cancer treatment.

Innovation Awards and Recognition NCCS's receipt of awards for innovation and design excellence demonstrates its commitment to technological advancement, suggesting an openness to integrating cutting-edge health tech, innovative IT systems, and patient engagement solutions.

Growing Support Programs The launch of programs for younger cancer survivors and return-to-work initiatives indicates a focus on holistic patient support, creating opportunities to offer patient management software, rehabilitation tech, and health education platforms that enhance survivorship and recovery.